ReviewPediatric nephrology (Berlin, Germany)2012
Glomerular pathology in Alport syndrome: a molecular perspective.
Review in Pediatric nephrology (Berlin, Germany), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 41 citations in OpenAlex.
- Pathological diagnosis of Alport syndrome.Kidney research and clinical practice · 2025Article
- Alport Syndrome: Clinical Spectrum and Therapeutic Advances.Kidney medicine · 2023Review
- The extracellular matrix complexity of idiopathic epiretinal membranes and the bilaminar arrangement of the associated internal limiting membrane in the posterior retina.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021Article
- Chronic Inflammation in Chronic Kidney Disease Progression: Role of Nrf2.Kidney international reports · 2021Review
- Ultrastructural Characterization of the Glomerulopathy in Alport Mice by Helium Ion Scanning Microscopy (HIM).Scientific reports · 2017Article
- A unified pathogenesis for kidney diseases, including genetic diseases and cancers, by the protein-homeostasis-system hypothesis.Kidney research and clinical practice · 2017Review
- Podocyte p53 Limits the Severity of Experimental Alport Syndrome.Journal of the American Society of Nephrology : JASN · 2016Article
- X-Linked Alport Dogs Demonstrate Mesangial Filopodial Invasion of the Capillary Tuft as an Early Event in Glomerular Damage.PloS one · 2016Article
- Pathological features of proteinuric nephropathy resembling Alport syndrome in a young Pyrenean Mountain dog.The Journal of veterinary medical science · 2015Article
- A mouse Col4a4 mutation causing Alport glomerulosclerosis with abnormal collagen α3α4α5(IV) trimers.Kidney international · 2014Article
- Diagnosis of Alport syndrome--search for proteomic biomarkers in body fluids.Pediatric nephrology (Berlin, Germany) · 2013Article
- Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-β1.Pediatric nephrology (Berlin, Germany) · 2013Article
- An update on the pathomechanisms and future therapies of Alport syndrome.Pediatric nephrology (Berlin, Germany) · 2013Review
- Alport syndrome--insights from basic and clinical research.Nature reviews. Nephrology · 2013Review
- Challenge in pathologic diagnosis of Alport syndrome: evidence from correction of previous misdiagnosis.Orphanet journal of rare diseases · 2012Article
- The role of cell-extracellular matrix interactions in glomerular injury.Experimental cell research · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
We have known for some time that mutations in the genes encoding 3 of the 6 type IV collagen chains are the underlying defect responsible for both X-linked (where the COL4A5 gene is involved) and autosomal (where either COL4A3 or COL4A4 genes are involved) Alport syndrome. The result of these mutations is the absence of the sub-epithelial network of all three chains in the glomerular basement membrane (GBM), resulting, at maturity, in a type IV collagen GBM network comprising only α1(IV) and α2(IV) chains. The altered GBM functions adequately in early life. Eventually, there is onset of proteinuria associated with the classic and progressive irregular thickening, thinning, and splitting of the GBM, which culminates in end-stage renal failure. We have learned much about the molecular events associated with disease onset and progression through the study of animal models for Alport syndrome, and have identified some potential therapeutic approaches that may serve to delay the onset or slow the progression of the disease. This review focuses on where we are in our understanding of the disease, where we need to go to understand the molecular triggers that set the process in motion, and what emergent therapeutic approaches show promise for ameliorating disease progression in the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.